# Safety and Dose Study of Peramivir for Influenza Treatment

> **NCT00297050** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 100 (—)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Peramivir

## Key facts

- **NCT ID:** NCT00297050
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02-23
- **Primary completion:** 2006-11-14
- **Final completion:** 2006-11-14
- **Target enrollment:** 100 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00297050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00297050, "Safety and Dose Study of Peramivir for Influenza Treatment". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00297050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*